XML 46 R32.htm IDEA: XBRL DOCUMENT v3.25.3
DEBT (Tables)
 12 Months Ended
Sep. 30, 2025
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt
Our indebtedness as of September 30, 2025 and September 30, 2024 is detailed in the table below. Refer below for discussion of the Revolving Credit Facility.
September 30, 2025September 30, 2024
Seller Note – Bolder BioPath (Related party)$150 $376 
Seller Note – Preclinical Research Services— 464 
Seller Payable - Orient BioResource Center3,235 3,700 
Seller Note – Histion (Related party)— 84 
Second Lien Notes23,220 17,846 
Convertible Senior Notes116,440 109,979 
Term Loan Facility, DDTL and Incremental Term Loans268,654 272,840 
Total debt before unamortized debt issuance costs$411,699 $405,289 
Less: Debt issuance costs not amortized(9,576)(11,950)
Total debt, net of unamortized debt issuance costs$402,123 $393,339 
Less: Current portion(402,123)(3,538)
Total Long-term debt$— $389,801 
Below are the weighted-average effective interest rates for the loans available under the Credit Agreement:
Twelve Months Ended
September 30,
202520242023
Effective interest rates:
Term Loan12.58 %11.39 %10.41 %
Initial DDTL12.53 %11.37 %10.41 %
Additional DDTL12.68 %11.50 %10.57 %
Schedule of Maturities of Long-Term Debt
The following table summarizes the amount of maturities of our total debt for each of the next five fiscal years and thereafter:
20262027202820292030ThereafterTotal
Debt$6,337 $297,337 $131,667 $— $— $— $435,341